Loading clinical trials...
Loading clinical trials...
This clinical study is in participants with Amyotrophic Lateral Sclerosis and is designed to evaluate the safety and tolerability of the gene therapy CTx1000.
Keep your clinical trial research organized — questions to ask, what to expect, and key details.
Lead Sponsor
Celosia Therapeutics Pty Ltd
Collaborators
NCT06051123 · ALSFTD, ALS (Amyotrophic Lateral Sclerosis), and more
NCT07235111 · Alzheimer Disease, FTD, and more
NCT07067229 · ALS (Amyotrophic Lateral Sclerosis)
NCT07175935 · ALS (Amyotrophic Lateral Sclerosis)
NCT06810219 · ALS (Amyotrophic Lateral Sclerosis)
Macquarie University Hospital
Sydney, New South Wales
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Start free trial →Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions